Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine

ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
Richard Rheingans Ph.D., Department Chair (Creator)
Appalachian State University (ASU )
Web Site:

Abstract: We evaluated the cost-effectiveness of rotavirus vaccination in Uzbekistan from the healthcare system and societal perspectives. Disease burden was estimated using national statistics on hospitalizations and deaths, and international estimates of under-?ve mortality. Without vaccination, the risk for rotavirus hospitalization by age 5 is 10 per 1000 children. Rotavirus hospitalizations cost US$ 406,000 annually, of which US$ 360,000 (89%) is for medical expenses and US$ 46,000 (11%) is for non-medical and indirect costs. Rotavirus mortality rate at 0.7 per 1000 derived from national data was three-fold lower than the same rate calculated from international estimates of under-?ve mortality. Rotavirus vaccination could reduce hospitalizations and deaths by 91% and avert US$ 370,000 in hospitalization costs alone. Vaccination would be cost-effective with vaccine prices in a range of US$ 2–25 per child. However, the cost-effectiveness is greatly in?uenced by mortality, vaccine price and vaccine ef?cacy.

Additional Information

R. Rheingans, E.T. Isakbaeva, E. Musabaev, L. Antil, R. Juraev,R.I. Glassand J.S. Bresee (2006) "Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine" Vaccine 25(2) pp. 373-380. Version of Record Available From
Language: English
Date: 2006
Rotavirus, Vaccine, Cost-effectiveness

Email this document to